Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.

Yazar: Haglund, C.
Baskı/Yayın Bilgisi 1986

Expression of laminin in benign and malignant sclerosing lesions of extrahepatic bile ducts.

Yazar: Haglund, C, Roberts, P J, Nordling, S
Baskı/Yayın Bilgisi 1989

Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.

Yazar: Kuusela, P., Haglund, C., Roberts, P. J.
Baskı/Yayın Bilgisi 1991

Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma.

Yazar: Haglund, C., Lindgren, J., Roberts, P. J., Nordling, S.
Baskı/Yayın Bilgisi 1991

Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis.

Yazar: Haglund, C., Lindgren, J., Roberts, P. J., Nordling, S.
Baskı/Yayın Bilgisi 1986

Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation

Yazar: Juuti, A, Nordling, S, Louhimo, J, Lundin, J, Haglund, C
Baskı/Yayın Bilgisi 2004

Cyclooxygenase‐2 expression correlates with poor prognosis in pancreatic cancer

Yazar: Juuti, A, Louhimo, J, Nordling, S, Ristimäki, A, Haglund, C
Baskı/Yayın Bilgisi 2006

The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.

Yazar: Lundin, J., Roberts, P. J., Kuusela, P., Haglund, C.
Baskı/Yayın Bilgisi 1994

Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.

Yazar: Kuusela, P., Haglund, C., Roberts, P. J., Jalanko, H.
Baskı/Yayın Bilgisi 1987

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.

Yazar: Haglund, C., Lundin, J., Kuusela, P., Roberts, P. J.
Baskı/Yayın Bilgisi 1994

Cellular fibronectin in serum and plasma: a potential new tumour marker?

Yazar: Ylätupa, S., Haglund, C., Mertaniemi, P., Vahtera, E., Partanen, P.
Baskı/Yayın Bilgisi 1995

Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA.

Yazar: Haglund, C., Ylätupa, S., Mertaniemi, P., Partanen, P.
Baskı/Yayın Bilgisi 1997

Tenascin-C in primary Merkel cell carcinoma

Yazar: Koljonen, V, Jahkola, T, Tukiainen, E, Granroth, G, Haglund, C, Böhling, T
Baskı/Yayın Bilgisi 2005

Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.

Yazar: Haglund, C., Lindgren, J., Roberts, P. J., Kuusela, P., Nordling, S.
Baskı/Yayın Bilgisi 1989

Impact of pasireotide on postoperative pancreatic fistulas following distal resections

Yazar: Vuorela, Tiina, Mustonen, H., Kokkola, A., Haglund, C., Seppanen, H.
Yayımlandı Langenbecks Arch Surg (2021)

Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.

Yazar: Halila, H., Huhtala, M. L., Haglund, C., Nordling, S., Stenman, U. H.
Baskı/Yayın Bilgisi 1987

MMP‐2 but not MMP‐9 associated with COX‐2 and survival in gastric cancer

Yazar: Mrena, J, Wiksten, J‐P, Nordling, S, Kokkola, A, Ristimäki, A, Haglund, C
Baskı/Yayın Bilgisi 2006

Preoperative serum levels of CEA and CA 242 in colorectal cancer.

Yazar: Carpelan-Holmström, M., Haglund, C., Kuusela, P., Järvinen, H., Roberts, P. J.
Baskı/Yayın Bilgisi 1995

Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.

Yazar: Jalanko, H, Kuusela, P, Roberts, P, Sipponen, P, Haglund, C A, Mäkelä, O
Baskı/Yayın Bilgisi 1984

Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.

Yazar: Haglund, C., Roberts, P. J., Kuusela, P., Scheinin, T. M., Mäkelä, O., Jalanko, H.
Baskı/Yayın Bilgisi 1986